Compare · IMDX vs ORKA
IMDX vs ORKA
Side-by-side comparison of Insight Molecular Diagnostics Inc. (IMDX) and Oruka Therapeutics Inc. (ORKA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both IMDX and ORKA operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- ORKA is the larger of the two at $5.59B, about 36.5x IMDX ($153.1M).
- Over the past year, IMDX is up 63.0% and ORKA is up 504.6% - ORKA leads by 441.5 points.
- IMDX has been more active in the news (6 items in the past 4 weeks vs 5 for ORKA).
- ORKA has more recent analyst coverage (11 ratings vs 0 for IMDX).
PerformanceIMDX+63.01%ORKA+504.56%
2025-07-17+0.00%2026-07-17
- Company
- Insight Molecular Diagnostics Inc.
- Oruka Therapeutics Inc.
- Price
- $4.76-0.83%
- $92.80+11.61%
- Market cap
- $153.1M
- $5.59B
- 1M return
- -9.85%
- +37.12%
- 1Y return
- +63.01%
- +504.56%
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- News (4w)
- 6
- 5
- Recent ratings
- 0
- 11
Latest IMDX
- Favorable Medicare Coverage Decision Supports Commercial Adoption of iMDx GraftAssure Assay Portfolio
- Director Silverman Lou covered exercise/tax liability with 7,700 shares, decreasing direct ownership by 12% to 55,807 units (SEC Form 4) (withholding tax)
- Director Last Andrew J. covered exercise/tax liability with 7,700 shares, decreasing direct ownership by 12% to 58,752 units (SEC Form 4) to satisfy withholding obligation
- Director Arno Andrew covered exercise/tax liability with 12,100 shares, decreasing direct ownership by 7% to 156,785 units (SEC Form 4) to cover withholding tax
- IMDx Chief Science Officer Ekkehard Schuetz Publishes 200th Research Paper
- iMDx and the American Society of Transplant Surgeons Announce Recipients of the ASTS-iMDx Health Economics Research Grant
- Insight Molecular Diagnostics Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Favorable Head-to-Head Data on iMDx's GraftAssure with Competing NGS Assay Published in Clinical Chemistry
- Director Silverman Lou was granted 26,943 shares, increasing direct ownership by 74% to 63,507 units (SEC Form 4)
- Director Last Andrew J. was granted 26,943 shares, increasing direct ownership by 68% to 66,452 units (SEC Form 4)
Latest ORKA
- Chief Medical Officer Goncalves Joana exercised 7,000 shares at a strike of $7.32 and sold $603,938 worth of shares (7,000 units at $86.28) as part of a pre-agreed trading plan (SEC Form 4)
- Senior Vice President, Finance Agarwal Arjun exercised 9,999 shares at a strike of $15.69 and sold $846,180 worth of shares (9,999 units at $84.63) as part of a pre-agreed trading plan (SEC Form 4)
- Director Fairmount Funds Management Llc converted options into 3,553,410 shares and sold $300,014,406 worth of shares (3,553,410 units at $84.43) (SEC Form 4)
- Chief Operating Officer Sandler Laura Lee exercised 5,000 shares at a strike of $7.80 and sold $472,079 worth of shares (5,000 units at $94.42) as part of a pre-agreed trading plan (SEC Form 4)
- Senior Vice President, Finance Agarwal Arjun sold $128,468 worth of shares (1,587 units at $80.95) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 15,312 units (SEC Form 4)
- Senior Vice President, Finance Agarwal Arjun exercised 9,459 shares at a strike of $15.88 and sold $687,035 worth of shares (9,854 units at $69.72) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 16,899 units (SEC Form 4) to cover taxes
- Chief Medical Officer Goncalves Joana sold $550,607 worth of shares (7,947 units at $69.28) as part of a pre-agreed trading plan and exercised 7,000 shares at a strike of $7.32, decreasing direct ownership by 3% to 32,718 units (SEC Form 4) (withholding tax)
- Chief Executive Officer Klein Lawrence Otto sold $120,494 worth of shares (1,729 units at $69.69), decreasing direct ownership by 0.19% to 925,580 units (SEC Form 4) to cover taxes
- Chief Operating Officer Sandler Laura Lee sold $41,814 worth of shares (600 units at $69.69), decreasing direct ownership by 0.25% to 236,384 units (SEC Form 4) (for tax liability)
- General Counsel Quinlan Paul T sold $51,083 worth of shares (733 units at $69.69), decreasing direct ownership by 2% to 31,034 units (SEC Form 4) (for withholding tax)